ArticleBone marrow transplantation2013
CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT.
Article in Bone marrow transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03150134 (Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.Bone marrow transplantation · 2015Trial
- Review
- Review
- Review
- Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation.Cells · 2024Review
- Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.Blood advances · 2023Article
- Utility of assessing CD3HLA · 2022Article
- Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML.Frontiers in oncology · 2022Review
- A practical guide to chimerism analysis: Review of the literature and testing practices worldwide.Human immunology · 2021Review
- Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.Cancer management and research · 2021Review
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?Frontiers in immunology · 2021Review
- Long-Term Mixed Chimerism AfterFrontiers in oncology · 2021Article
- Review
- Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.Bone marrow transplantation · 2020Article
- Article
- Article
- Mutation Clearance after Transplantation for Myelodysplastic Syndrome.The New England journal of medicine · 2018Article
- Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.Annals of hematology · 2018Article
- Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Bone marrow transplantation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After allo-SCT, analysis of CD34(+) lineage-specific donor cell chimerism (DCC) is a sensitive method for monitoring minimal residual disease in patients with AML or myelodysplastic syndrome (MDS) with CD34 expression. To substantiate evidence of whether immune interventions in patients with impending relapse, defined by incomplete lineage-specific DCC, may prevent hematological relapse, we performed a retrospective nested case control study. Unsorted and lineage-specific DCC were measured in 134 patients. Forty-three patients had an incomplete CD34(+)-DCC with no other evidence of relapse. After immediate tapering of immunosuppressive treatment (30 patients) and/or infusion of donor lymphocytes (10 patients), 21 patients remained in remission (conversion to complete lineage-specific DCC) and 22 relapsed. Relapse-free survival at 3 years of the 91 patients with stable DCC and of the 43 patients with incomplete DCC was 74% (95% confidence interval (CI), 64-83%) and 40% (95% CI, 24-58%), respectively. OS rates were 79% (95% CI, 70-88%) and 52% (95% CI, 35-69%), respectively. These results, with 49% of patients with impending relapse successfully treated with immune intervention, highly suggest that analysis of CD34(+)-DCC is an important tool for monitoring and the management of AML and MDS patients after allo-SCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.